Coala Life is a Swedish medical technology and life science company founded in 2014 with the aim to revolutionize heart diagnostics and digital health. Their flagship solution, the Coala, is a patented and commercially available service for remote monitoring and self-screening of heart sounds and ECG. With CE and FDA clearance, the Coala is offered to both consumers and healthcare professionals through Coala Pro, facilitating smart, digital cardiac assessments.
Driven by the alarming statistics of cardiovascular diseases being among the leading global causes of death, Coala Life aligns its mission with the vital need for early diagnosis. The company's journey started as a research project in 2004, led by Swedish physicians and researchers determined to transform the status quo. The Coala system, which effectively replaces the 18th-century stethoscope with digital technology, encompasses a suite of patents and sophisticated algorithms for listening, measuring, and analyzing heart data, enabling early detection and treatment of various heart conditions.
Backed by a $10.00M Venture Round investment on 24 April 2019, with participation from 20 North Street, Larry Leksell, and Anders Nyrén, Coala Life stands at the forefront of innovation in the Health Care sector, offering a transformative solution to enhance heart health monitoring and diagnostics.
Overall, Coala Life's dedication to empowering individuals in monitoring their heart health and its disruptive approach to cardiovascular diagnostics positions it as a promising investment opportunity with significant potential for positive impact in the healthcare industry.